Table 1. Summary of clinical and molecular features of the DLBCL casesa.

Parameter	Cohort 1				Cohort 2
	De novo		Transformed		De novo		Transformed
	No. of informative	No. of cases	No. of informative	No. of cases	No. of informative	No. of cases	No. of informative	No. of cases
Gender	56		19		37		9
Male		31		10		13		3
Female		25		9		24		6
Age at diagnosis (median)	56 (68 years)		19 (66 years)		37 (63 years)		9 (69 years)
⩽ median		30		11		19		5
> median		26		8		18		4
Stage	53		19		36		7
I		13		1		17		3
II		16		5		7		0
III		10		6		9		2
IV		14		7		3		2
Regime treatment	48		18		36		9
CHOP		22		7		5		3
R-CHOP		17		7		17		4
No treatment		1		0		5		0
Others		8		4		9		2
IPI score	51		19		36		6
Low (0-1-2)		36		13		27		4
High (3-4-5)		15		6		9		2
GCB phenotype	54		16		35		9
GCB		20		13		18		5
non-GCB		34		3		17		4
BCL2 expression	55		0		20		3
Negative		17		—		9		1
Positive		38		—		11		2
BCL6 expression	54		16		35		9
Negative		30		5		15		3
Positive		24		11		20		6
IRF4 expression	54		16		35		9
Negative		22		11		16		4
Positive		32		5		19		5
CD10 expression	54		16		35		9
Negative		35		3		23		5
Positive		19		13		12		4
Follow-up	56		0		35		8
Alive		24		—		26		4
Dead		10		—		1		0
DOD		22		—		8		4

Abbreviation: DOD=dead of disease.

^aData partly published in previous studies.^{3, 4, 13, 14}